English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  De novo Protein Design of Vascular Endothelial Growth Factor Inhibitors

Maksymenko, K., Skokowa, J., Lupas, A., Müller, P., & ElGamacy, M. (2021). De novo Protein Design of Vascular Endothelial Growth Factor Inhibitors. Protein Science, 30(Supplement 1): 140, 61.

Item is

Basic

show hide
Genre: Meeting Abstract

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Maksymenko, K1, Author           
Skokowa, J, Author
Lupas, A1, Author                 
Müller, P, Author                 
ElGamacy, M1, Author                 
Affiliations:
1Department Protein Evolution, Max Planck Institute for Developmental Biology, Max Planck Society, ou_3375791              

Content

show
hide
Free keywords: -
 Abstract: Growth factors are signaling molecules coordinating the complex functionality of multicellular organisms during development and homeostasis. The activity of signaling networks needs to be tightly controlled; otherwise, aberrant expression of growth factors can cause diverse disorders such as cancer, autoimmune and cardiovascular diseases. Being highly specific and able to target various molecular surfaces, protein-based binders constitute a powerful means to manipulate signaling interactions. In contrast to the common antibody development technologies, which are empirically guided and often yield binders to irrelevant epitopes, de novo protein design methods allow targeting arbitrarily selected functional sites. Additionally, de novo design offers control over protein sequence and topology, facilitating improvements in folding kinetics, protein stability, and solubility. Here, we present our work on in silico design of the epitope-directed inhibitors against vascular endothelial growth factor (VEGF), a key modulator of tumor progression. Taking advantage of a new computational approach for massivescale docking of a target epitope against a protein structure database, we selected several scaffolds with high shape complementarity to the receptor binding site of VEGF. After further interface design, aiming to minimize the estimated binding free energy, a small set of best candidates (16 proteins) was experimentally evaluated. Biophysical measurements revealed that the binding affinities of the designs to VEGF ranged from nano- to micromolar levels. X-ray structure determination of one of the candidates showed atomic-level agreement with the design model. Moreover, in vitro assays showed the ability of the best designs to inhibit proliferation of VEGF-dependent acute myeloid leukemia cells. Thus, our results not only provide potential anti-cancer therapeutic candidates, but also demonstrate the feasibility of the rational approach to design high-affinity protein binders against predefined conformational motifs of the target molecules. This generalizable approach can be deployed to generate novel leads for future research and therapeutic purposes.

Details

show
hide
Language(s):
 Dates: 2021-10
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1002/pro.4191
 Degree: -

Event

show
hide
Title: 35th Anniversary Symposium of The Protein Society
Place of Event: -
Start-/End Date: 2021-07-07 - 2021-07-14

Legal Case

show

Project information

show

Source 1

show
hide
Title: Protein Science
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Hoboken, New Jersey, Vereinigte Staaten : Wiley
Pages: - Volume / Issue: 30 (Supplement 1) Sequence Number: 140 Start / End Page: 61 Identifier: ISSN: 0961-8368
CoNE: https://pure.mpg.de/cone/journals/resource/954925342760